Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results.
The ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) trial was a randomized, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve the outcomes of patients undergoing coronary stenting. A total of 2064 patients undergoing stent implantation in a native coronary artery were enrolled. Patients were randomly allocated to receive eptifibatide, given as two 180-g/kg boluses 10 minutes apart and a continuous infusion of 2.0 g/kg-minute for 18 to 24 hours, or placebo, in addition to aspirin, heparin, and a thienopyridine. The primary end point was the composite of death, myocardial infarction (MI), urgent target vessel revascularization (TVR), and thrombotic "bailout" GP IIb/IIIa inhibitor therapy within 48 hours after randomization. The key secondary end point was the composite of death, MI, or urgent TVR at 30 days.
O'Shea
J. Conor
JC
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA. oshea002@mc.duke.edu
Tcheng
James E.
JE